Ascendis Pharma (ADR)
Builds and commercializes rare-endocrinology medicines through the TransCon prodrug platform.
$247.91
After-hours close0.00 (0.00%)
At close$247.91(−0.58%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 108.03%Insiders 0.83%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 62.11M · Float 61.56M · 99.1% free float
Institutions13F, as of Jun 30, 2026
332 holders · 67.10M shares · 93 new positions · 192 increased · 95 reduced · 53 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10.28M | 16.55% | +10.28Mnew | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 6.75M | 10.88% | +592.8K | Aug 14, 2026 |
| Avoro Capital Advisors LLC | 5.11M | 8.23% | +5.11Mnew | Aug 14, 2026 |
| Westfield Capital Management Co LP | 4.80M | 7.73% | +4.80Mnew | Aug 12, 2026 |
| Jupiter Topco LLC | 3.65M | 5.87% | +3.65Mnew | Aug 14, 2026 |
| FMR LLC | 3.55M | 5.71% | +3.55Mnew | Aug 13, 2026 |
| Artisan Partners Limited Partnership | 2.63M | 4.24% | +2.63Mnew | Aug 13, 2026 |
| BlackRock, Inc. | 2.21M | 3.56% | +2.21Mnew | Aug 7, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 9.90% | 6.16M | 13G | May 7, 2026 ↗ |
| Westfield Capital Management Company, L.P. | 8.48% | 5.19M | 13G | Feb 11, 2026 ↗ |
| FMR LLC | 8.00% | 4.65M | 13G | May 12, 2025 ↗ |
| Janus Henderson Group PLC | 6.00% | 3.72M | 13G | May 15, 2026 ↗ |
| Artisan Partners Asset Management Inc. | 5.20% | 3.23M | 13G | Feb 3, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Jan Moller Mikkelsen | director | 453.4K | 0.73% | Mar 18, 2026 |
| Kennett Sprogoe | officer: See Remarks | 19.6K | 0.03% | Mar 18, 2026 |
| Anni Lotte Kirstine Sonderbjerg Pedersen | officer: EVP & Chief Admin Officer | 19.5K | 0.03% | Mar 18, 2026 |
| Scott Thomas Smith | officer: EVP & Chief Financial Officer | 4.4K | 0.01% | Jun 2, 2026 |
| Lars Holtug | director | 4.2K | 0.01% | Mar 18, 2026 |
| Albert Cha | director | 3.7K | 0.01% | Mar 18, 2026 |
| Jean Jacques Bienaime | director | 2.9K | 0.00% | Aug 18, 2026 |
| Siham Imani | director | 2.3K | 0.00% | Mar 18, 2026 |
| William Fairey | director | 2.1K | 0.00% | Mar 18, 2026 |
| Lisa Morrison | director | 1.6K | 0.00% | Mar 18, 2026 |
1 ten-percent owner holds 8.66M shares by Form 4, outside the officers-and-directors figure above · 2 people have not refiled in the last 18 months (17.32M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Jean Jacques Bienaimedirector | Purchase · 2 lots | 2,000 | $246.33 | 2,900 |
| Jun 2, 2026 | Scott Thomas Smithofficer: EVP & Chief Financial Officer | Purchase | 100 | $219.00 | 4,367 |
| May 29, 2026 | Scott Thomas Smithofficer: EVP & Chief Financial Officer | Purchase | 250 | $223.32 | 4,267 |
| May 29, 2026 | Jean Jacques Bienaimedirector | Purchase · 3 lots | 500 | $223.12 | 900 |
| May 26, 2026 | Jean Jacques Bienaimedirector | Purchase · 2 lots | 400 | $237.80 | 400 |
| May 11, 2026 | Flemming Steen Jensenofficer: See Remarks | Sale | 19,460 | $238.49 | 0 |
CongressHouse and Senate disclosures
Not reported.